Literature DB >> 7718279

CT and MRI of diffuse liver disease.

N M Rofsky1, H Fleishaker.   

Abstract

CT and MRI contribute important information to the clinical evaluation of diffuse liver disease. In some cases, these modalities can establish a diagnosis that was not ascertained histologically, which is often the case when sampling errors prevent a definitive tissue diagnosis. Characteristic alterations of liver attenuation on CT, signal changes on MRI, and morphological changes appreciated with both modalities can be used to diagnose fatty infiltration, some parenchymal deposition diseases, and cirrhosis. Furthermore, hepatocellular disease can be confirmed in the setting of indeterminate clinical and laboratory findings. Significant overlap in the imaging findings of this wide range of disorders continues to limit specificity; however, at a minimum, these techniques provide a rapid means to a noninvasive evaluation that often guides clinical decisions. Faster scanning techniques available with CT and MRI may provide additional information by assessing contrast dynamics. This review of CT and MRI in diffuse liver disease considers the diagnostic utility and clinical implications of these modalities. Pathological findings relevant to imaging considerations are discussed.

Entities:  

Mesh:

Year:  1995        PMID: 7718279     DOI: 10.1016/0887-2171(95)90012-8

Source DB:  PubMed          Journal:  Semin Ultrasound CT MR        ISSN: 0887-2171            Impact factor:   1.875


  21 in total

Review 1.  Magnetic resonance imaging quantification of liver iron.

Authors:  Claude B Sirlin; Scott B Reeder
Journal:  Magn Reson Imaging Clin N Am       Date:  2010-08       Impact factor: 2.266

Review 2.  Non-alcoholic fatty liver disease: The diagnosis and management.

Authors:  Shehab M Abd El-Kader; Eman M Salah El-Den Ashmawy
Journal:  World J Hepatol       Date:  2015-04-28

3.  Reoperation after mitral valve repair in viewpoints of kidney injury as well as hemolytic anemia.

Authors:  Ryo Ishida; Takaomi Adachi; Yayoi Shiotsu; Mami Ishida; Yasukiyo Mori; Kiyoshi Doi; Keiichi Tamagaki
Journal:  CEN Case Rep       Date:  2014-10-18

Review 4.  Therapy for alcoholic liver disease.

Authors:  Maryconi M Jaurigue; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 5.  Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.

Authors:  Dharmesh H Kaswala; Michelle Lai; Nezam H Afdhal
Journal:  Dig Dis Sci       Date:  2016-03-26       Impact factor: 3.199

6.  Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C.

Authors:  A K P Lim; S D Taylor-Robinson; N Patel; R J Eckersley; R D Goldin; G Hamilton; G R Foster; H C Thomas; D O Cosgrove; M J K Blomley
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

Review 7.  Quantification of liver iron with MRI: state of the art and remaining challenges.

Authors:  Diego Hernando; Yakir S Levin; Claude B Sirlin; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2014-03-03       Impact factor: 4.813

8.  Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: a cross sectional study.

Authors:  M J K Blomley; A K P Lim; C J Harvey; N Patel; R J Eckersley; R Basilico; R Heckemann; A Urbank; D O Cosgrove; S D Taylor-Robinson
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

9.  Computed tomography findings for predicting severe acute hepatitis with prolonged cholestasis.

Authors:  Sang Jung Park; Jin Dong Kim; Yeon Seok Seo; Beom Jin Park; Min Ju Kim; Soon Ho Um; Chang Ha Kim; Hyung Joon Yim; Soon Koo Baik; Jin Yong Jung; Bora Keum; Yoon Tae Jeen; Hong Sik Lee; Hoon Jai Chun; Chang Duck Kim; Ho Sang Ryu
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

10.  [Value of magnetic resonance imaging in diffuse liver diseases].

Authors:  N Schramm; M D'Anastasi; M F Reiser; C J Zech
Journal:  Radiologe       Date:  2012-08       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.